Nattopharma (Norway)

Recent papers from Nattopharma (Norway)

1. Osteomodulin attenuates smooth muscle cell osteogenic transition in vascular calcificationClinical and Translational Medicine · 2022
2. Combining phosphate binder therapy with vitamin K2 inhibits vascular calcification in an experimental animal model of kidney failureNephrology Dialysis Transplantation · 2021
3. Vitamin K antagonist use induces calcification and atherosclerotic plaque progression resulting in increased hypercoagulabilityEuropean Heart Journal Open · 2021
4. Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilateJournal of Thrombosis and Haemostasis · 2021
5. Menaquinone-7 Supplementation Improves Osteogenesis in Pluripotent Stem Cell Derived Mesenchymal Stem CellsFrontiers in Cell and Developmental Biology · 2021
6. Vitamin K: Double Bonds beyond Coagulation Insights into Differences between Vitamin K1 and K2 in Health and DiseaseInternational Journal of Molecular Sciences · 2019
7. The Bone—Vasculature Axis: Calcium Supplementation and the Role of Vitamin KFrontiers in Cardiovascular Medicine · 2019
8. Inhibition of TNF-α, IL-1α, and IL-1β by Pretreatment of Human Monocyte-Derived Macrophages with Menaquinone-7 and Cell Activation with TLR Agonists In VitroJournal of Medicinal Food · 2016
9. New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs)Nutrients · 2015
10. Vitamin K–containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7Blood · 2006